ClinicalTrials.gg
CompletedNCT04911907Updated Apr 3, 2026

Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Solid Tumors

A Phase 2 interventional study of utidelone injection in Solid Tumor, sponsored by Beijing Biostar Pharmaceuticals Co., Ltd.. Completed at 3 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-03.

Sponsored by Beijing Biostar Pharmaceuticals Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jan 2021, registered May 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
126
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This trial is an open, two-stage, multi-center, phase II clinical trial to evaluate the efficacy and safety of Utidelone in advanced solid tumors (excluding breast cancer, lung cancer, and colorectal cancer) that have failed standard of treatment or were unable to perform standard treatment.

This trial is divided into 2 stages, screening stage and expansion stage. In the screening stage, 10 patients were enrolled for each tumor type(including Squamous cell carcinoma of head and neck, Esophageal cancer, Stomach cancer, Pancreatic cancer, Cholangiocarcinoma, Ovarian cancer and Other solid tumors). Based on the results of the tumor type screening stage, the sponsor and the main investigator will have a discussion and have the alignment of tumor types to enter the expansion stage. The expansion stage will refine the inclusion / exclusion criteria and may adjust the treatment plan based on the tumor type and the combination drug selection. A total of 30-50 patients (including patients enrolled in the screening stage) were enrolled in each specified tumor type during the expansion stage.

02

Conditions studied

  • Solid Tumor
03

In context

Lead sponsor

Beijing Biostar Pharmaceuticals Co., Ltd. is the lead sponsor of 14 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically documented locally-advanced and/or solid (including Squamous cell carcinoma of head and neck, Esophageal cancer, Stomach cancer, Pancreatic cancer, Cholangiocarcinoma, Ovarian cancer and Other solid tumors) that is incurable, and has failed prior standard therapy or for which standard therapy is not appropriate.
  2. Have based on Response Criteria in Solid Tumors Version 1.1 ( 1.1)
  3. Age 18 -70 years old
  4. performance status of 0-1
  5. ≥ 3 months
  6. Basically normal results from routine blood test within 1 week prior to enrollment

    1. (ANC) >= 1.5 x 10\^9/L
    2. >= 9 g/dL
    3. >= 80 x 10\^9/L
  7. Basically normal liver and renal functions within 1 week prior to enrollment

    1. total =\< 1.5 x with direct bilirubin within normal range
    2. (ALT) and aspartate aminotransferase (AST) =\< 3 x ULN (ALT and AST =\< 5 x ULN is acceptable if liver metastases are present)
    3. >=50 ml/min
  8. Women and men of must agree to take effective measures during the study and within six months after the last treatment. Female patients must have negative urinary pregnancy test within 7 days before the first treatment ( women must have no menstruation for at least 12 months before they are considered unable to conceive)
  9. Patients who give written with good compliance.

Exclusion criteria

Exclusion Criteria:

  1. Received chemotherapy, radiotherapy, biological therapy, endocrine therapy, immunotherapy and other anti-tumor treatments within 4 weeks prior to enrollment while participating in this trial, except for the following items:

    1. Nitrosourea or mitomycin C is within 6 weeks before the first dosage of the study drug;
    2. Oral fluorouracil and small molecule targeted drugs are 2 weeks before the first use of the study drug or 5 half-life periods of the drug (whichever is longer);
    3. The traditional Chinese medicine with anti-tumor indication is within 2 weeks before the first use of the research medicine.
  2. Received other unlaunched clinical research drugs or treatment within 4 weeks before the first dosage of the research drug.
  3. Have undergone major organ surgery (excluding needle ) or experienced significant trauma within 4 weeks prior to the first dosage of study drug, or require elective surgery during the trial period.
  4. Symptomatic peripheral neuropathy 5.0 grade evaluation ≥ grade 2
  5. With severe allergies to castor oil, or have had serious adverse reactions with anti-microtubule drugs in the past
  6. Patients of pregnancy or breast feeding
  7. Patients with AEs caused by any previous treatment (including systemic and local treatment) that have not yet restored to GRADE 1 (excluding hair loss)
  8. Patient with known active central nervous system (CNS) and/or carcinomatous meningitis.
  9. Patients with active infections and currently need systemic anti-infective treatment
  10. Patient with immunodeficiency, including a positive antibody test.
  11. Patients with history of active (hepatitis B virus titer> ), allow prophylactic antiviral treatment other than interferon; have a history of virus infection (hepatitis C antibody positive).
  12. Patients with history of serious cardiovascular and cerebrovascular diseases.
  13. Patients with mental disorders or patients with poor compliance.
  14. Patients not fitted for this study determined by the investigators.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
126 participants (actual)

Study arms

  • Experimental
    Squamous cell carcinoma of head and neck: Utidelone Injection

    Cohort 1 Squamous cell carcinoma of head and neck. Participants will be treated with utidelone monotherapy

    Drug: utidelone injection

  • Experimental
    Esophageal cancer: Utidelone injection

    Cohort 2 Esophageal cancer. Participants will be treated with utidelone monotherapy.

    Drug: utidelone injection

  • Experimental
    Stomach cancer: Utidelone injection

    Cohort 3 Stomach cancer. Participants will be treated with utidelone monotherapy.

    Drug: utidelone injection

  • Experimental
    Pancreatic cancer: Utidelone Injection

    Cohort4 Pancreatic cancer. Participants will be treated with Utidelone monotherapy.

    Drug: utidelone injection

  • Experimental
    Ovarian cancer: Utidelone Injection

    Cohort5 Ovarian cancer. Participants will be treated with Utidelone monotherapy.

    Drug: utidelone injection

  • Experimental
    Cholangiocarcinoma: Utidelone

    Cohort 6 Cholangiocarcinoma. Participants will be treated with Utidelone monotherapy

    Drug: utidelone injection

  • Experimental
    Other solid tumors: Utidelone Injection

    Cohort 7 Other solid tumors. Participants will be treated with Utidelone monotherapy

    Drug: utidelone injection

Interventions

  • Utidelone monotherapy 35 mg/m2/day IV transfusing over 90 min. on day 1-day 5 of each 21 day cycle

06

What researchers measure

Primary outcomes

  1. Tumor response to utidelone treatment

    Reflected by percentage of tumor size reduction or regression, assessed by imaging techniques and expressed as Objective Response Rate (ORR) ORR is defined as the proportion of patients with a best overall response of Complete Response (CR) or Partial Response (PR) according to RECIST. 1.1.

    Time frame: 12 months from first study treatment

Secondary outcomes

  1. Clinical benefit rate (CBR)

    Time frame: 12 months from first study treatment

  2. Progression free survival (PFS)

    PFS is defined as the duration of time from first study treatment to disease progression or death from any cause as documented by the investigator

    Time frame: 18 months from first study treatment

  3. Safety profile associated with utidelone injection

    Observe and record incidence of Treatment-Emergent Adverse Events and severe adverse effects associated with utidelone injection

    Time frame: 18 months from first study treatment

07

Study locations

3 sites
  • Luhe Hospital, Capital Medical University
    Beijing, China
  • Obstetrics and Gynecology Hospital, Capital Medical University
    Beijing, China
  • Shanghai East Hospital of Tongji University
    Shanghai, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2021 to primary completion in May 2025, 52 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2021
First posted
Jun 3, 2021
StartActual
Jan 22, 2021
Primary completionActual
May 31, 2025
CompletionActual
May 31, 2025
Last update
Apr 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04911907
Lead sponsor
Beijing Biostar Pharmaceuticals Co., Ltd.
Collaborators
Chengdu Biostar Pharmaceuticals
Responsible party
Sponsor
First posted
Jun 3, 2021
Start date
Jan 22, 2021
Primary completion
May 31, 2025
Completion
May 31, 2025
Last update
Apr 3, 2026

Study contacts

JIN LI, MD
principal investigator · Shanghai Tongji University Affiliated Oriental Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Desoxyepothilone B

Start the discussion